AVDL
Avadel Pharmaceuticals plc
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · IE
$21.64
+0.00%Income statement
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 248.5M | 169.1M | 28.0M | — | — |
| Cost of Revenue | 13.8M | 15.3M | 846.0K | — | — |
| Gross Profit | 234.8M | 153.8M | 27.1M | — | — |
| Operating Expenses | |||||
| R&D Expense | 39.9M | 15.2M | 13.3M | 20.7M | 17.1M |
| SG&A Expense | 190.3M | 181.0M | 151.7M | 74.5M | 68.5M |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | 3.3M | (53.0K) |
| Total Operating Expenses | 230.2M | 196.2M | 165.0M | 98.6M | 85.5M |
| Cost and Expenses | 244.0M | 211.5M | 165.8M | 98.6M | 85.5M |
| Operating Income (EBIT) | 4.5M | (42.4M) | (137.8M) | (98.6M) | (85.5M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | 9.7M | 10.8M | 9.9M | 12.3M | 9.9M |
| Net Interest Income | (9.7M) | (10.8M) | (9.9M) | (12.3M) | (9.9M) |
| Other Non-Op Income/Expense | (7.8M) | (6.7M) | (22.9M) | (12.9M) | (7.6M) |
| Non-Operating Income (excl Interest) | (1.9M) | (4.2M) | 13.0M | 536.0K | (2.3M) |
| EBT (Pre-Tax Income) | (3.3M) | (49.1M) | (160.8M) | (111.4M) | (93.1M) |
| Income Tax Expense | (3.0M) | (247.0K) | (501.0K) | 26.0M | (15.8M) |
| Bottom Line | |||||
| Net Income | (278.0K) | (48.8M) | (160.3M) | (137.5M) | (77.3M) |
| Earnings from Cont. Ops | (278.0K) | (48.8M) | (160.3M) | (137.5M) | (77.3M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (278.0K) | (48.8M) | (160.3M) | (137.5M) | (77.3M) |
| Per Share | |||||
| Basic EPS | $0.00 | ($0.51) | ($2.00) | ($2.29) | ($1.32) |
| Diluted EPS | $0.00 | ($0.51) | ($2.00) | ($2.29) | ($1.32) |
| Revenue Per Share | $2.56 | $1.78 | $0.35 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 97.1M | 95.1M | 80.2M | 60.1M | 58.5M |
| Diluted Shares Outstanding | 101.3M | 95.1M | 80.2M | 60.1M | 58.5M |
| Profitability Metrics | |||||
| EBITDA | 10.1M | (35.6M) | (149.1M) | (97.6M) | (82.4M) |
| D&A | 3.7M | 2.7M | 1.8M | 1.5M | 815.0K |
| EBIT | 6.5M | (38.2M) | (150.9M) | (99.1M) | (83.2M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Sep 1, 2025